Abstract PS1-10-30: Real-world treatment utilization and outcomes of trastuzumab deruxtecan (T-DXd) among patients with hormone receptor-positive (HR+) HER2-low metastatic breast cancer (mBC) in the United States
Observational study describes treatment outcomes and utilization of T-DXd in HR+ HER2-low metastatic breast cancer, indicating implications for earlier treatment initiation.
Key Points
This research aims to analyze the real-world treatment utilization and outcomes of trastuzumab deruxtecan in patients with hormone receptor-positive HER2-low metastatic breast cancer.
Retrospective longitudinal observational cohort study
Utilization of de-identified patient-level data from Flatiron Health database
Inclusion of patients aged ≥18 with HER2-low metastatic breast cancer treated with T-DXd
Assessment of demographic and clinical characteristics at T-DXd initiation
Descriptive statistics and Kaplan-Meier method for time-to-event analysis
1232 patients were included, with a median age of 64 years
T-DXd was initiated as first-line therapy for 7.3%, and ≥4L therapy for 51.1% of patients
Overall median follow-up was 14 months
Median real-world time to next treatment was shorter for patients initiating T-DXd in later lines compared to earlier lines